Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04458922 · ClinicalTrials.gov registry record · Phase 2
Testing Atezolizumab in People 2-17 Years Old With Clear Cell Sarcoma or Advanced Chondrosarcoma
A Phase 2 study of Metastatic Primary Central Chondrosarcoma and Unresectable Primary Central Chondrosarcoma, sponsored by National Cancer Institute (NCI).
- Active
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
- 15
- Study locations
NCT04458922 is a Phase 2 study of Metastatic Primary Central Chondrosarcoma and Unresectable Primary Central Chondrosarcoma that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 27 participants. The trial reports 15 study locations across 11 states.
The verdict
NCT04458922, a Phase 2 study of Metastatic Primary Central Chondrosarcoma and Unresectable Primary Central Chondrosarcoma, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
- 15
- Study locations
Study Summary
This phase II trial studies how well atezolizumab works in treating patients with chondrosarcoma or clear cell sarcoma that is newly diagnosed, cannot be removed by surgery (unresectable), or has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Computed Tomography
- DRUG Atezolizumab
- PROCEDURE Biopsy Procedure
Study Locations (15)
Maryland
- National Cancer Institute Developmental Therapeutics Clinic - Bethesda
- National Institutes of Health Clinical Center - Bethesda
- NCI - Center for Cancer Research - Bethesda
Georgia
- Emory University Hospital Midtown - Atlanta
- Emory University Hospital/Winship Cancer Institute - Atlanta
Missouri
- Washington University School of Medicine - St Louis
- Siteman Cancer Center-South County - St Louis
California
- USC / Norris Comprehensive Cancer Center - Los Angeles
Florida
- UF Health Cancer Institute - Gainesville - Gainesville
Massachusetts
- Dana-Farber Cancer Institute - Boston
Ohio
- Ohio State University Comprehensive Cancer Center - Columbus
Pennsylvania
- University of Pittsburgh Cancer Institute (UPCI) - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2020-10-05 |
| Est. Completion | 2026-12-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04458922
The ClinicalTrials.gov registry entry for NCT04458922 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Metastatic Primary Central Chondrosarcoma appearing as the primary indexed condition, and to 4 interventions - of which Biospecimen Collection is the first listed.
NCT04458922 reports 15 study locations spanning 11 distinct geographic areas - top geographies include Maryland, Georgia, Missouri.
Frequently Asked Questions
What is clinical trial NCT04458922 about?
NCT04458922 is a clinical study titled "Testing Atezolizumab in People 2-17 Years Old With Clear Cell Sarcoma or Advanced Chondrosarcoma". This phase II trial studies how well atezolizumab works in treating patients with chondrosarcoma or clear cell sarcoma that is newly diagnosed, cannot be removed by surgery (unresectable), or has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as atezo...
What is the current status of trial NCT04458922?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2020-10-05. Estimated completion is 2026-12-17.
What conditions does trial NCT04458922 study?
This clinical trial studies the following conditions: Metastatic Primary Central Chondrosarcoma, Unresectable Primary Central Chondrosarcoma, Dedifferentiated Chondrosarcoma, Central Chondrosarcoma, Grade 2, Central Chondrosarcoma, Grade 3.
What interventions are being tested in trial NCT04458922?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Atezolizumab (DRUG), Biopsy Procedure (PROCEDURE).
Who is sponsoring clinical trial NCT04458922?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04458922 being conducted?
This trial has 15 study locations across California, Florida, Georgia, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Primary Central Chondrosarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Metastatic Primary Central Chondrosarcoma
All registered trials for this condition
Unresectable Primary Central Chondrosarcoma
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.